Document is current
Any future updates will be listed below
-
Authors
Zhong, Xiaofang https://orcid.org/0000-0001-8831-5733
Li, Qiongyu
Polacco, Benjamin J
Patil, Trupti
Marley, Aaron
Foussard, Helene
Khare, Prachi
Vartak, Rasika
Xu, Jiewei
DiBerto, Jeffrey F
Roth, Bryan L https://orcid.org/0000-0002-0561-6520
Eckhardt, Manon https://orcid.org/0000-0001-8143-6129
von Zastrow, Mark https://orcid.org/0000-0003-1375-6926
Krogan, Nevan J https://orcid.org/0000-0003-4902-337X
Hüttenhain, Ruth https://orcid.org/0000-0002-0896-5910
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute on Drug Abuse (R01DA056354, R37DA045657)
DOD | Defense Advanced Research Projects Agency (HR0011-19-2-0020, HR0011-20-2-0029)
HHS | NIH | National Heart, Lung, and Blood Institute (P01HL146366)
- License Information
-
More Information
Article History
Received: 7 April 2023
Revised: 9 June 2024
Accepted: 11 June 2024
First Online: 1 July 2024
Disclosure and competing interests statement
: The Krogan Laboratory has received research support from Vir Biotechnology, F Hoffmann-La Roche, and Rezo Therapeutics. NJK has a financially compensated consulting agreement with Maze Therapeutics. NJK is the President and is on the Board of Directors of Rezo Therapeutics, and he is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, and Interline Therapeutics. BLR is a member of the Scientific Advisory Boards of Septerna Pharmaceuticals, Escient Pharmaceuticals, Onsero Pharmaceuticals, and Levator.
